Scholarlink

<p><i>Candida albicans</i> causes systemic infections with 20–50% mortality in critically ill and immunocompromised patients, despite antifungal treatment. Current therapies face limitations, including toxicity and resistance, underscoring the need for prophylactic vaccines. This study presents a novel divalent liposomal vaccine, delivering <i>C. albicans</i> Cht3 and Sap2 antigens. Vaccination induced protective Th1/Th17 immunity, a balanced Th1/Th2 ratio, antigen-specific antibodies, and boosted macrophage activity, improving survival in a mouse model of invasive candidiasis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pre-clinical evaluation of a divalent liposomal vaccine to control invasive candidiasis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月13日

查看全文
  • Augusto Costa-Barbosa,
  • Maria Inês Pacheco,
  • Andreia C. Gomes,
  • Tony Collins,
  • Manuel Vilanova,
  • Célia Pais,
  • Alexandra Correia,
  • Paula Sampaio

摘要

Candida albicans causes systemic infections with 20–50% mortality in critically ill and immunocompromised patients, despite antifungal treatment. Current therapies face limitations, including toxicity and resistance, underscoring the need for prophylactic vaccines. This study presents a novel divalent liposomal vaccine, delivering C. albicans Cht3 and Sap2 antigens. Vaccination induced protective Th1/Th17 immunity, a balanced Th1/Th2 ratio, antigen-specific antibodies, and boosted macrophage activity, improving survival in a mouse model of invasive candidiasis.